+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target



Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target



International Journal of Clinical and Experimental Pathology 7(7): 3918-3927



Melanoma-associated antigen D4 (MAGE-D4) is a novel member of MAGE family. This study aimed to examine the expression and immunogenicity of MAGE-D4 in colorectal cancer (CRC) to determine its potential as a prognosis and immunotherapeutic target. The expression of MAGE-D4 mRNA and protein was determined by RT-PCR and immunohistochemistry (IHC) in CRCs with paired adjacent non-tumor tissues, colorectal adenomas and normal colorectal tissues, respectively. Sera from 64 CRC patients were tested for MAGE-D4 antibody by ELISA. MAGE-D4 mRNA was more frequently expressed in CRCs (76.7%, 46/60) than in adjacent non-tumor tissues (15.0%, 9/60). MAGE-D4 protein was detected in all the CRC tissues tested, 70.0% of which showed high expression. There was no MAGE-D4 protein detected in any paired adjacent non-tumor tissue. No MAGE-D4 expression was found in colorectal adenomas and normal colorectal tissues by either RT-PCR or immunohistochemistry. Patients with high MAGE-D4 protein expression had significantly shorter overall survival than those with low MAGE-D4 protein expression (median, 68.6 vs 122.2 months; P=0.030). Furthermore, multivariate analysis exhibited high MAGE-D4 protein expression had a trend toward an independent prognostic factor (hazard ratio: 6.124; P=0.050). Humoral immunity to MAGE-D4 was detected in 12 of 64 (18.8%) CRC patients' sera but not in 77 healthy donors. There was no correlation between MAGE-D4 expression, serum antibody and clinicopathological parameters. These findings suggest MAGE-D4 may serve as a potentially prognostic biomarker and an attractive target of immunotherapy in CRC.

(PDF emailed within 1 workday: $29.90)

Accession: 054818953

Download citation: RISBibTeXText

PMID: 25120768


Related references

Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable. JAMA Oncology: -, 2016

Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer. Journal of Experimental & Clinical Cancer Research 34(): 13-13, 2016

Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology 10(): 125-125, 2016

c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf Journal of Oncology 1(14): 28-34, 2016

Increased expression of TBX2 is a novel independent prognostic biomarker of a worse outcome in colorectal cancer patients after curative surgery and a potential therapeutic target. Medical Oncology 30(4): 688-688, 2014

High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32(45): 5901-5907, 2015

Prognostic value of MAGE-A9 expression in patients with colorectal cancer. Clinics and Research in Hepatology and Gastroenterology 40(2): 239-245, 2015

New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. Journal of Clinical Pathology 68(11): 913-916, 2016

Should we consider cancer/testis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma?. Histopathology 58(3): 481-483, 2011

Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World Journal of Gastroenterology 12(35): 5651-5657, 2006

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. Journal of Pathology 238(4): 562-570, 2016

PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. Plos One 9(7): E103021-E103021, 2015

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. British Journal of Ophthalmology 96(3): 451-458, 2012

LncRNA Sox2ot overexpression serves as a poor prognostic biomarker in gastric cancer. American Journal of Translational Research 8(11): 5035-5043, 2016

May autophagy be a novel biomarker and antitumor target in colorectal cancer?. Biomarkers in Medicine 10(10): 1081-1094, 2016